Estrone and estradiol and T 2 DM risk in men

METHODSdCross-sectional relationships of estradiol and estrone levels with diabetes were assessed at examination 7 (1998–2001) in FHS generation 2 men (n = 1,458); prospective associations between hormone levels at examination 7 and incident diabetes were assessed 6.8 years later at examination 8. Type 2 diabetesmellitus was defined as fasting glucose.125mg/dL, medication use, or both. Estradiol, estrone, and testosterone levels were measured with liquid chromatography tandem mass spectrometry, and free estradiol and estrone were calculated.

[1]  J. Murabito,et al.  Age trends in estradiol and estrone levels measured using liquid chromatography tandem mass spectrometry in community-dwelling men of the Framingham Heart Study. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[2]  Jalal Hejazi,et al.  Association between tamoxifen treatment and diabetes , 2012, Cancer.

[3]  J. Sowers,et al.  Loss of Estrogen Receptor α Signaling Leads to Insulin Resistance and Obesity in Young and Adult Female Mice , 2012, Cardiorenal Medicine.

[4]  A. Meikle.  Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts , 2012 .

[5]  J. Elmquist,et al.  Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. , 2011, Cell metabolism.

[6]  J. Gustafsson,et al.  Estrogen receptors and the metabolic network. , 2011, Cell metabolism.

[7]  David Handelsman,et al.  Standardization of hormonal assays for the 21st century. , 2010, The Journal of clinical endocrinology and metabolism.

[8]  U. Kintscher,et al.  Metabolic impact of estrogen signalling through ERalpha and ERbeta , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  I. Njølstad,et al.  Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. , 2010, European journal of endocrinology.

[10]  Norman A. Mazer,et al.  A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: With illustrative examples from male and female populations , 2009, Steroids.

[11]  D. Levy,et al.  Contemporary trends in dyslipidemia in the Framingham Heart Study. , 2009, Archives of internal medicine.

[12]  R. Vasan,et al.  The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders , 2008, Steroids.

[13]  J. Bergquist,et al.  High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol. , 2008, American journal of clinical pathology.

[14]  R. Urban,et al.  Effects of raloxifene on insulin sensitivity, beta-cell function, and hepatic insulin extraction in normal postmenopausal women. , 2008, Fertility and sterility.

[15]  S. Cummings,et al.  Comparison of methods to measure low serum estradiol levels in postmenopausal women. , 2006, The Journal of clinical endocrinology and metabolism.

[16]  E. Ding,et al.  Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. , 2006, JAMA.

[17]  L. Niskanen,et al.  Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. , 2004, Diabetes care.

[18]  G. Zou,et al.  A modified poisson regression approach to prospective studies with binary data. , 2004, American journal of epidemiology.

[19]  F. Stanczyk,et al.  Limitations of direct estradiol and testosterone immunoassay kits , 2003, Steroids.

[20]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[21]  E. Barrett-Connor,et al.  Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. , 2003, Clinical therapeutics.

[22]  E. Vittinghoff,et al.  Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial , 2003, Annals of Internal Medicine.

[23]  A. Chang,et al.  Aging and insulin secretion. , 2003, American journal of physiology. Endocrinology and metabolism.

[24]  B. Bengtsson,et al.  Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. , 2002, The Journal of clinical endocrinology and metabolism.

[25]  E. Barrett-Connor,et al.  Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. , 2002, Diabetes care.

[26]  E. Barrett-Connor,et al.  Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. , 2000, Diabetes care.

[27]  J. Mckinlay,et al.  Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. , 2000, Diabetes care.

[28]  N. Wareham,et al.  Hormone replacement therapy and glucose tolerance in EPIC‐Norfolk: a population‐based study , 2000, Diabetes/metabolism research and reviews.

[29]  M. Espeland,et al.  Effect of Postmenopausal Hormone Therapy on Glucose and Insulin Concentrations , 1998, Diabetes Care.

[30]  A. Folsom,et al.  Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal Women , 1993 .

[31]  E. Barrett-Connor,et al.  Endogenous sex hormone levels in older adult men with diabetes mellitus. , 1990, American journal of epidemiology.

[32]  T. Dawber,et al.  Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.